



31 January – 6 February

COMPANY SPOTLIGHT

- **Ceragenix Pharmaceuticals, Inc.** (Denver) announced a silicon device using its Company's CeraShield(TM) antimicrobial technology has achieved 120 days of continuous antimicrobial efficacy. The silicon ring was tested against E. coli bacteria through daily soaking in a liquid containing at least 1,000 colony forming units ("CFUs") of the bacteria per milliliter. This technology has potential use in its ring form to prevent sexually transmitted diseases and as a coating on silicone urinary catheters to prevent urinary tract infections.
- **Allos Therapeutics, Inc.** (Westminster) announced final results from its pivotal Phase 2 PROPEL trial of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). As previously reported in preliminary results released in early December, 27% of patients achieved a response (full or partial), the study's primary endpoint. Final results showed the Kaplan-Meier estimate for the median duration of response, a key secondary endpoint, to be 287 days or 9.4 months. Based on these results, Allos plans to file a New Drug Application with the FDA in the first half of the year.
- **Baxa Corporation** (Englewood) was ranked 7th on the 2009 list of the Top 50 Family-Owned Companies in Colorado by Colorado BizMagazine. Baxa, a medical device company focused on developing solutions for handling, measuring and administering fluid medications, was founded in 1975 by Brian Baldwin and Ronald Baxa. The Baldwin family continues to play an active role in the company's day-to-day business operations.
- **Array Biopharma Inc.** (Boulder) reported results for Q2 2009 of its fiscal year. The company reported revenues of \$7.7M and R&D expenditures of \$23.7M, and a net loss of \$37.8M. This loss included a \$10.5M loss from a mark-to-market write down of auction grade securities. Array finished the quarter with \$100M in cash and equivalents on hand and already announced plans last month to curtail spending. Despite these cutbacks, Array is still pursuing eight clinical programs in the areas of cancer, inflammatory and metabolic diseases and three new discovery programs.
- **Covidien Inc.** (Boulder) is manufacturing a new endotracheal tube that reduces the incidents of pneumonia associated with long-term intubation. The new design and technology used in the Mallinckrodt SealGuard Evac tube have been clinically demonstrated to reduce the incidence of both early- and late-onset ventilator-associated pneumonia.
- **Amgen Inc** (Boulder, Longmont) said on Friday its drug Nplate was approved by European Union regulators to treat a rare clotting disorder that can cause dangerous bleeding. The injectable drug helps stimulate bone marrow into producing blood platelets in patients with chronic immune thrombocytopenic purpura (ITP). The European Commission approved use of the drug for patients only after other available treatments fail to help. Nplate was approved by the U.S. Food and Drug Administration last year.

SQUARE PEGS

- **The Northern Colorado Health Research Coalition** presented an event on the "Emergence of Drug Resistant Infectious Disease" on Wednesday night in Fort Collins. A recap of the presentations is available [here](#).

- Looking for new strategies for managing your company's cash flow during this economic lull? Now is the time to check out [BIO Business Solutions](#), BIO's cost-savings program. With 15 money-saving opportunities with leading providers in the biotech industry, saving your company money is made easier with BIO Business Solutions. Participation is free to members of BIO and 38 state/regional biotech associations. Get a complete list of the products and services available to you [here](#).

UPCOMING EVENTS

- CBSA will hold a free webinar on how to use Beaker.com, the bioscience industry's web-portal, on February, 11 at 10:30 am. Registration details are available [here](#).
- CBSA's next BioBreakfast will take place on February 18 at 7:30 am and cover "Marketing your company to the media successfully – How to's of PR." More information and registration information are available [here](#).
- T.R. Reid, veteran Washington Post Correspondent and presenter at BioWest 2008, will present twice in Fort Collins on February 19. He will speak at noon at the Lory Student Center West Ballroom at CSU and at 7 pm at the Fort Collins Marriott. Both events are free and will focus on critical choices facing the US healthcare system guided by comparisons to other countries.

LEGISLATIVE UPDATE

- CBSA's lobbying team, have provided this week's legislative report.